company background image
6747

Brighten Optix TPEX:6747 Stock Report

Last Price

NT$192.00

Market Cap

NT$4.6b

7D

-6.6%

1Y

-43.5%

Updated

01 Oct, 2022

Data

Company Financials +
6747 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance2/6
Financial Health6/6
Dividends2/6

6747 Stock Overview

Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region.

Brighten Optix Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Brighten Optix
Historical stock prices
Current Share PriceNT$192.00
52 Week HighNT$479.50
52 Week LowNT$190.00
Beta0.42
1 Month Change-10.49%
3 Month Change-12.73%
1 Year Change-43.53%
3 Year Changen/a
5 Year Changen/a
Change since IPO50.01%

Recent News & Updates

Shareholder Returns

6747TW Medical EquipmentTW Market
7D-6.6%-3.9%-5.0%
1Y-43.5%-8.3%-18.0%

Return vs Industry: 6747 underperformed the TW Medical Equipment industry which returned -8.3% over the past year.

Return vs Market: 6747 underperformed the TW Market which returned -18% over the past year.

Price Volatility

Is 6747's price volatile compared to industry and market?
6747 volatility
6747 Average Weekly Movement2.7%
Medical Equipment Industry Average Movement5.4%
Market Average Movement5.1%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 6747 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 6747's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/ahttps://www.brightenoptix.com.tw

Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region. The company offers hard contact lenses under HiClear and Soclear brands; soft contact lenses under Brio+moist, iDealsoft, and MyOKvision names; contact lens care potion under the Oxy vision plus Briomoist and Mu likang brands; and other ancillary products, as well as night-wear orthokeratology hard contact lenses. Brighten Optix Corporation is based in Taipei, Taiwan.

Brighten Optix Fundamentals Summary

How do Brighten Optix's earnings and revenue compare to its market cap?
6747 fundamental statistics
Market CapNT$4.64b
Earnings (TTM)NT$241.71m
Revenue (TTM)NT$716.56m

19.2x

P/E Ratio

6.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6747 income statement (TTM)
RevenueNT$716.56m
Cost of RevenueNT$228.37m
Gross ProfitNT$488.19m
Other ExpensesNT$246.48m
EarningsNT$241.71m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)9.99
Gross Margin68.13%
Net Profit Margin33.73%
Debt/Equity Ratio0%

How did 6747 perform over the long term?

See historical performance and comparison

Dividends

4.5%

Current Dividend Yield

87%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 6747 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6747?

Other financial metrics that can be useful for relative valuation.

6747 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA13.7x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 6747's PE Ratio compare to its peers?

6747 PE Ratio vs Peers
The above table shows the PE ratio for 6747 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average25.3x
4126 Pacific Hospital Supply
13.6x6.2%NT$4.9b
1786 SciVision Biotech
27.4xn/aNT$3.1b
4771 Vizionfocus
32.3xn/aNT$6.7b
6612 ICARES Medicus
28xn/aNT$2.8b
6747 Brighten Optix
19.2xn/aNT$4.6b

Price-To-Earnings vs Peers: 6747 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (25.3x).


Price to Earnings Ratio vs Industry

How does 6747's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

Price-To-Earnings vs Industry: 6747 is expensive based on its Price-To-Earnings Ratio (19.2x) compared to the TW Medical Equipment industry average (18.9x)


Price to Earnings Ratio vs Fair Ratio

What is 6747's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6747 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6747's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 6747 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6747 (NT$192) is trading below our estimate of fair value (NT$234.92)

Significantly Below Fair Value: 6747 is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Brighten Optix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.9%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6747's forecast earnings growth is above the savings rate (0.7%).

Earnings vs Market: Insufficient data to determine if 6747's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 6747's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 6747's revenue (20.9% per year) is forecast to grow faster than the TW market (7.7% per year).

High Growth Revenue: 6747's revenue (20.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6747's Return on Equity is forecast to be low in 3 years time (19.1%).


Discover growth companies

Past Performance

How has Brighten Optix performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


32.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6747 has a high level of non-cash earnings.

Growing Profit Margin: 6747's current net profit margins (33.7%) are lower than last year (36.5%).


Past Earnings Growth Analysis

Earnings Trend: 6747's earnings have grown significantly by 32.7% per year over the past 5 years.

Accelerating Growth: 6747's earnings growth over the past year (6.3%) is below its 5-year average (32.7% per year).

Earnings vs Industry: 6747 earnings growth over the past year (6.3%) underperformed the Medical Equipment industry 19%.


Return on Equity

High ROE: 6747's Return on Equity (21.6%) is considered high.


Discover strong past performing companies

Financial Health

How is Brighten Optix's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 6747's short term assets (NT$948.9M) exceed its short term liabilities (NT$328.2M).

Long Term Liabilities: 6747's short term assets (NT$948.9M) exceed its long term liabilities (NT$44.6M).


Debt to Equity History and Analysis

Debt Level: 6747 is debt free.

Reducing Debt: 6747 has no debt compared to 5 years ago when its debt to equity ratio was 49.8%.

Debt Coverage: 6747 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 6747 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Brighten Optix current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


4.52%

Current Dividend Yield

Dividend Yield vs Market

Brighten Optix Dividend Yield vs Market
How does Brighten Optix dividend yield compare to the market?
SegmentDividend Yield
Company (Brighten Optix)4.5%
Market Bottom 25% (TW)2.6%
Market Top 25% (TW)7.0%
Industry Average (Medical Equipment)3.9%
Analyst forecast in 3 Years (Brighten Optix)5.7%

Notable Dividend: 6747's dividend (4.52%) is higher than the bottom 25% of dividend payers in the TW market (2.59%).

High Dividend: 6747's dividend (4.52%) is low compared to the top 25% of dividend payers in the TW market (7%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 6747 has been paying a dividend for less than 10 years.

Growing Dividend: 6747's dividend payments have increased, but the company has only paid a dividend for 2 years.


Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (86.9%), 6747's payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (121.5%), 6747's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Brighten Optix has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 6747?
Owner TypeNumber of SharesOwnership Percentage
Institutions2,673,23511.1%
General Public21,515,76588.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 5 shareholders own 11.05% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.59%
Matthews International Capital Management, LLC
2,079,000NT$399.2m0%0.08%
1.97%
Grandeur Peak Global Advisors, LLC
476,000NT$91.4m-5.74%0.07%
0.19%
Nikko Asset Management Co., Ltd.
47,000NT$9.0m0%no data
0.17%
Dimensional Fund Advisors LP
42,259NT$8.1m0.31%no data
0.12%
Taishin Securities Investment Trust Co. Ltd.
28,976NT$5.6m0.08%0.04%

Company Information

Brighten Optix Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Brighten Optix Corporation
  • Ticker: 6747
  • Exchange: TPEX
  • Founded: NaN
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: NT$4.644b
  • Shares outstanding: 24.19m
  • Website: https://www.brightenoptix.com.tw

Location

  • Brighten Optix Corporation
  • No.150, Chengde Road
  • 6th Floor-1
  • Taipei
  • 11167
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6747TPEX (Taipei Exchange)YesOrdinary SharesTWTWDOct 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.